People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sudo Biosciences, Inc. | — | Biotech / Pharma | Series C | $73.1M | $685.8M | 2023 |
| Santa Ana Bio, Inc. | — | Biotechnology | Series B | $63.3M | $150.6M | 2023 |
Shinichiro Fuse at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shinichiro Fuse on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Jerel Davis | 1 | 13 |
| Thomas Woiwode | 1 | 7 |
| Bhaskar Chaudhuri | 1 | 3 |
| Daniel Estes | 1 | 3 |
| Peter Emtage | 1 | 2 |
| Brendan Bulik-Sullivan | 1 | 2 |
| Marcelo Bigalo | 1 | 1 |
| Edd Fleming | 1 | 1 |
| Chris Gagliardi | 1 | 1 |
| Scott Byrd | 1 | 1 |
| Jim Bristol | 1 | 1 |
| Mittie Doyle | 1 | 1 |
| Christine Borowski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.